Search Results
Aug 06, 2026, 23:02 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Aug 04, 2026, 06:15 ET SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
More news about: SOPHiA GENETICS
Aug 04, 2026, 06:15 ET SOPHiA GENETICS Enters Collaboration to Develop Companion Diagnostics for Precision Oncology Therapies
collaboration to develop, validate, and deploy two companion diagnostics (CDx) supporting precision oncology therapies with AstraZeneca (LSE/STO/NYSE: AZN).
More news about: SOPHiA GENETICS
Jul 30, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 23, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 16, 2026, 10:07 ET AstraZeneca (AZN) Securities Investigation Notice - Levi & Korsinsky
participate in the AZN investigation?A: Investors who purchased AZN stock or securities and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.Q: What if I already sold my AZN shares -- can I still
More news about: Levi & Korsinsky, LLP
Jul 16, 2026, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of AstraZeneca PLC- AZN
2026 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AstraZeneca PLC ("AstraZeneca" or the "Company") (NYSE: AZN). Such investors are advised to contact Danielle Peyton at [email protected] or
More news about: Pomerantz LLP
Jul 10, 2026, 09:00 ET AZN SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving AstraZeneca
the United States.Frequently Asked Questions About the AZN InvestigationQ: What is the AZN securities fraud investigation about? A: A securities investigation is pending concerning AstraZeneca (NYSE: AZN) regarding potentially materially false or misleading statements.
More news about: SueWallSt.com
Jul 09, 2026, 20:58 ET AstraZeneca Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into AstraZeneca (AZN)
Asked Questions About the AZN InvestigationQ: Who is conducting the AZN investigation? A: Levi & Korsinsky, LLP is investigating potential securities fraud claims on behalf of investors who purchased AZN securities. The firm is
More news about: Levi & Korsinsky, LLP
Jul 06, 2026, 08:55 ET As AI Models Become Commodities, a Bio-Native AI Company Just Moved to Patent the Data Layer Beneath the Models
landscape that includes public names investors track such as Absci (NASDAQ: ABSI), Certara (NASDAQ: CERT), AstraZeneca (NASDAQ: AZN), and NVIDIA (NASDAQ: NVDA), each distinct, and none a proxy for MindWalk.Patenting the Layer Beneath the ModelThe premise
More news about: USA News Group
Jul 01, 2026, 21:00 ET Abbisko Therapeutics and AstraZeneca Enter a Strategic Collaboration to Conduct the Clinical Trial of Lumipodlin (ABSK043), a First-in-Class Oral PD-L1 Inhibitor, in Combination with TAGRISSO® for NSCLC
Therapeutics" hereafter, HKEX code: 02256.HK) today announced that it has entered into a strategic collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN) to jointly advance the clinical development of a novel IO-TKI combination therapy for non-small cell lung cancer (NSCLC). As a multicenter, open-label
More news about: Abbisko
Jun 05, 2026, 08:55 ET NYSE Content Update: AstraZeneca Celebrates Largest Transfer in NYSE History
5thInvestors are reacting to the May jobs report after the DOW climbed to a record close on Thursday.AstraZeneca (NYSE: AZN) is celebrating its February transfer to the NYSE, the largest transfer by market capitalization in the NYSE's 234-year history.NYSE
More news about: New York Stock Exchange
Apr 29, 2026, 19:00 ET Pinetree Therapeutics Announces Exercise of Option to License EGFR Degrader Program by AstraZeneca
pioneering next-generation targeted protein degradation approaches for cancer and other serious diseases, today announced that AstraZeneca (LSE/STO/NYSE: AZN) has exercised its option under the companies' previously announced
More news about: PineTree Therapeutics
Mar 03, 2026, 17:31 ET Chronic Kidney Disease Market Poised to Expand Significantly During Forecast Period (2025-2034) as Demand for Early Diagnosis and Novel Therapies Increases | DelveInsight
Chronic Kidney Disease CompaniesAstraZeneca (LON: AZN), Boehringer Ingelheim, Mineralys Therapeutics (NASDAQ: MLYS), ProKidney (NASDAQ: PROK), Disc Medicine (NASDAQ: IRON), Regeneron Pharmaceuticals (NASDAQ:
More news about: DelveInsight Business Research, LLP
Mar 02, 2026, 17:31 ET Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight
to increase over the forecast period.Leading biliary tract cancer companies, such as TransThera Sciences (HKG: 2617), AstraZeneca (LON: AZN), J-Pharma, OHARA Pharmaceutical (TYO: 5218), Compass Therapeutics (NASDAQ: CMPX), Merck (NYSE: MRK), Eisai (TYO: 4523), Seagen (NASDAQ: SGEN), Pfizer
More news about: DelveInsight Business Research, LLP
Feb 11, 2026, 17:31 ET EGFR-NSCLC Market to Observe Stunning Growth at a CAGR of 9.6% During the Forecast Period (2025-2034) | DelveInsight
Diamond Therapeutics (NASDAQ: BDTX), Lantern Pharma (NASDAQ: LTRN), Dizal Pharmaceutical (SHA: 688192), Daiichi Sankyo (TYO: 4568), AstraZeneca (LON: AZN), Jiangsu Hansoh Pharmaceutical, Boehringer Ingelheim, Pfizer (NYSE: PFE), Johnson & Johnson Innovative Medicine (NYSE: JNJ), Yuhan Corporation (KRX:
More news about: DelveInsight Business Research, LLP
Feb 10, 2026, 08:30 ET Novel Serotonergic Agonists Positioned to Capture Share of $150B+ Neuropsychiatric Market
Johnson (NYSE: JNJ), AbbVie Inc. (NYSE: ABBV), Takeda Pharmaceutical Company Limited (NYSE: TAK) and AstraZeneca PLC (NYSE: AZN).
More news about: Market News Updates
Oct 09, 2025, 06:00 ET Turbine Launches Collaboration with AstraZeneca, Leveraging Turbine's Virtual Disease Models to Rationalize ADC Discovery
Turbine, a leading company specializing in virtualizing biological experiments with AI, today announced a collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to test the ability of Turbine's platform to rationalize antibody-drug conjugate (ADC) discovery by predicting response mechanisms, informing ADC positioning,
More news about: Turbine
Sep 22, 2025, 08:00 ET SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the
More news about: SOPHiA GENETICS
Sep 22, 2025, 08:00 ET SOPHiA GENETICS Expands Collaboration with AstraZeneca to Enhance Detection of Breast and Prostate Cancer
SOPH), an AI technology company transforming precision medicine, today announced an expansion of its collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) from the
More news about: SOPHiA GENETICS
Sep 17, 2025, 08:30 ET Advancing Cancer Research Brings New Hope for Patients Worldwide
innovators — including Iovance Biotherapeutics Inc. (NASDAQ: IOVA), Merck & Co. Inc. (NYSE: MRK), AstraZeneca PLC (NASDAQ: AZN) and Bristol-Myers Squibb Co. (NYSE: BMY) — that are driving advances in these challenging therapeutic areas.
More news about: NetworkNewsWire